# Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

> **NCT06729593** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 87 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Remdesivir
- **BIOLOGICAL:** Remdesivir Placebo
- **DRUG:** Corticosteroid

## Key facts

- **NCT ID:** NCT06729593
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-20
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-11-20
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-10-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06729593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06729593, "Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06729593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*